Local Income Levels, Reference Pricing Key To Fix Pricing Of Patented Drugs In India
This article was originally published in PharmAsia News
Executive Summary
A draft circulated by the Department of Pharmaceuticals hopes to provide clarity on pricing of patented drugs in India, but it could lead to heated debate and further complicate pricing strategies for drug makers. The government says it will stick to the core objective to lower health care costs for the masses.
You may also be interested in...
U.K. Value-Based Pricing Negotiations Could Help NICE-Rejected Cancer Drugs
Negotiations will start in September 2012 on a value-based pricing approach for new medicines in the U.K., and on a new PPRS scheme for currently marketed drugs, with a new suggestion: oncologics previously rejected by NICE might be reviewed again under the new VBP system.
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.